Table of Content

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary : Global Nephropathic Cystinosis Treatment Market


4. Market Overview

4.1. Introduction

4.1.1. Treatment Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, 2017–2027

4.4.1. Market Revenue Projections (US$ Mn)

4.5. Porter’s Five Force Analysis


5. Key Insights

5.1. 5.1.Regulatory Scenario by Region/globally

5.2. 5.2.Pipeline Analysis

5.3. 5.3.Nephropathic Cystinosis Epidemiology: Overview


6. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Treatment Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Treatment Type, 2017–2027

6.3.1. Therapy

6.3.1.1. Systemic Depletion Therapy

6.3.1.2. Symptomatic Therapy

6.3.2. Renal Transplantation

6.4. Market Attractiveness, by Treatment Type, 2019–2027


7. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Sales Channel

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Sales Channel, 2017–2027

7.3.1. Hospitals

7.3.2. Specialty/Retail Pharmacies

7.3.3. Others

7.4. Market Attractiveness, by Sales Channel, 2019–2027


8. Global Nephropathic Cystinosis Treatment Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia Pacific

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness, by Region, 2019–2027


9. North America Nephropathic Cystinosis Treatment Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast, by Treatment Type, 2017–2027

9.2.1. Therapy

9.2.1.1. Systemic Depletion Therapy

9.2.1.2. Symptomatic Therapy

9.2.2. Renal Transplantation

9.3. Market Value Forecast, by Sales Channel, 2017–2027

9.3.1. Hospitals

9.3.2. Specialty/Retail Pharmacies

9.3.3. Others

9.4. Market Value Forecast, by Country, 2017–2027

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis, 2019–2027

9.5.1. By Treatment Type

9.5.2. By Sales Channel

9.5.3. By Country


10. Europe Nephropathic Cystinosis Treatment Market Analysis and Forecast

10.1. Introduction

10.1.1. Key Findings

10.2. Market Value Forecast, by Treatment Type, 2017–2027

10.2.1. Therapy

10.2.1.1. Systemic Depletion Therapy

10.2.1.2. Symptomatic Therapy

10.2.2. Renal Transplantation

10.3. Market Value Forecast, by Sales Channel, 2017–2027

10.3.1. Hospitals

10.3.2. Specialty/Retail Pharmacies

10.3.3. Others

10.4. Market Value Forecast, by Country/Sub-region, 2017–2027

10.4.1. Germany

10.4.2. U.K.

10.4.3. France

10.4.4. Spain

10.4.5. Italy

10.4.6. Rest of Europe

10.5. Market Attractiveness Analysis, 2019–2027

10.5.1. By Treatment Type

10.5.2. By Sales Channel

10.5.3. By Country/Sub-region


11. Asia Pacific Nephropathic Cystinosis Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Treatment Type, 2017–2027

11.2.1. Therapy

11.2.1.1. Systemic Depletion Therapy

11.2.1.2. Symptomatic Therapy

11.2.2. Renal Transplantation

11.3. Market Value Forecast, by Sales Channel, 2017–2027

11.3.1. Hospitals

11.3.2. Specialty/Retail Pharmacies

11.3.3. Others

11.4. Market Value Forecast, by Country/Sub-region, 2017–2027

11.4.1. China

11.4.2. Japan

11.4.3. India

11.4.4. Australia & New Zealand

11.4.5. Rest of Asia Pacific

11.5. Market Attractiveness Analysis, 2019–2027

11.5.1. By Treatment Type

11.5.2. By Sales Channel

11.5.3. By Country/Sub-region


12. Latin America Nephropathic Cystinosis Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Treatment Type, 2017–2027

12.2.1. Therapy

12.2.1.1. Systemic Depletion Therapy

12.2.1.2. Symptomatic Therapy

12.2.2. Renal Transplantation

12.3. Market Value Forecast, by Sales Channel, 2017–2027

12.3.1. Hospitals

12.3.2. Specialty/Retail Pharmacies

12.3.3. Others

12.4. Market Value Forecast, by Country/Sub-region, 2017–2027

12.4.1. Brazil

12.4.2. Mexico

12.4.3. Rest of Latin America

12.5. Market Attractiveness Analysis, 2019–2027

12.5.1. By Treatment Type

12.5.2. By Sales Channel

12.5.3. By Country/Sub-region

13. Middle East & Africa Nephropathic Cystinosis Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Treatment Type, 2017–2027

13.2.1. Therapy

13.2.1.1. Systemic Depletion Therapy

13.2.1.2. Symptomatic Therapy

13.2.2. Renal Transplantation

13.3. Market Value Forecast, by Sales Channel, 2017–2027

13.3.1. Hospitals

13.3.2. Specialty/Retail Pharmacies

13.3.3. Others

13.4. Market Value Forecast, by Country/Sub-region, 2017–2027

13.4.1. GCC Countries

13.4.2. South Africa

13.4.3. Rest of Middle East & Africa

13.5. Market Attractiveness Analysis, 2019–2027

13.5.1. By Treatment Type

13.5.2. By Sales Channel

13.5.3. By Country/Sub-region

14. Competition Landscape

14.1. Market Player – Competition Matrix (By Tier and Size of companies)

14.2. Market Share/Position Analysis, by Company (2018)

14.3. Company Profiles

14.3.1. Horizon Therapeutics plc.

14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.1.2. Company Financials

14.3.1.3. Growth Strategies

14.3.1.4. SWOT Analysis

14.3.2. Mylan N.V.

14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.2.2. Company Financials

14.3.2.3. Growth Strategies

14.3.2.4. SWOT Analysis

14.3.3. Chiesi Farmaceutici SpA

14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.3.2. Company Financials

14.3.3.3. Growth Strategies

14.3.3.4. SWOT Analysis

14.3.4. Recordati Rare Diseases

14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.4.2. Company Financials

14.3.4.3. Growth Strategies

14.3.4.4. SWOT Analysis

14.3.5. AVROBIO, Inc.

14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.5.2. Company Financials

14.3.5.3. Growth Strategies

14.3.5.4. SWOT Analysis

14.3.6. Leadiant Biosciences, Inc.

14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.6.2. Company Financials

14.3.6.3. Growth Strategies

14.3.6.4. SWOT Analysis

14.3.7. Eloxx Pharmaceuticals

14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.7.2. Company Financials

14.3.7.3. Growth Strategies

14.3.7.4. SWOT Analysis

14.3.8. GlaxoSmithKline plc

14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

14.3.8.2. Company Financials

14.3.8.3. Growth Strategies

14.3.8.4. SWOT Analysis



List of Figures



Figure 01: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, 2017–2027

Figure 03: Global Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018

Figure 04: Global Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018

Figure 05: Global Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018

Figure 06: Global Nephropathic Cystinosis Treatment Market Value Share, by Region, 2018

Figure 07: Regulatory Approval Process - U.S.

Figure 08: Regulatory Approval Process - Europe

Figure 09: Regulatory Approval Process - Japan

Figure 10: Global Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 11: Global Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 12: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Therapy, 2017-2027

Figure 13: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Renal Replacement, 2017-2027

Figure 14: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 15: Global Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 16: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027

Figure 17: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty/Retail Pharmacies, 2017–2027

Figure 18: Global Nephropathic Cystinosis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027

Figure 19: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 20: Global Nephropathic Cystinosis Treatment Market Value Share, by Region, 2018 and 2027

Figure 21: Global Nephropathic Cystinosis Treatment Market Attractiveness, by Region, 2019–2027

Figure 22: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 23: North America Nephropathic Cystinosis Treatment Market Value Share, by Country, 2018 and 2027

Figure 24: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Country, 2019–2027

Figure 25: North America Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 26: North America Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 27: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 28: North America Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 29: North America Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 30: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 31: Europe Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 32: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027

Figure 33: Europe Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 34: Europe Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 35: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 36: Europe Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 37: Europe Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 38: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 39: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 40: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027

Figure 41: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 42: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 43: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 44: Asia Pacific Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 45: Asia Pacific Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 46: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 47: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 48: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027

Figure 49: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 50: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 51: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 52: Latin America Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 53: Latin America Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 54: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 55: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Country/Sub-region, 2018 and 2027

Figure 56: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Country/sub-region, 2019–2027

Figure 57: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Treatment Type, 2018 and 2027

Figure 58: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Therapy, 2018 and 2027

Figure 59: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Treatment Type, 2019–2027

Figure 60: Middle East & Africa Nephropathic Cystinosis Treatment Market Value Share, by Sales Channel, 2018 and 2027

Figure 61: Middle East & Africa Nephropathic Cystinosis Treatment Market Attractiveness, by Sales Channel, 2019–2027

Figure 62: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Figure 63: Horizon Therapeutics plc, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 64: Horizon Therapeutics plc, Breakdown of Pharmaceutical Division Net Sales, by Region, 2018

Figure 65: Horizon Therapeutics plc, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Figure 66: Horizon Therapeutics plc, Breakdown of Net Sales, by Business Segment, 2018

Figure 67: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 68: Mylan N.V. Breakdown of Net Sales, by Region, 2018

Figure 69: Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018

Figure 70: CHIESI Farmaceutici S.p.A., Breakdown of Net Sales (%), by Region, 2018

Figure 71: CHIESI Farmaceutici S.p.A., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 72: CHIESI Farmaceutici S.p.A., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 73: Recordati Group - Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 74: Recordati Group - R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018

Figure 75: Recordati Group - Breakdown of Net Sales (%), by Region, 2018

 

List of Tables


List of Tables

Table 01: Pipeline Analysis- Nephropathic Cystinosis

Table 02: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 03: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 04: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

Table 05: Global Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 06: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027

Table 07: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 08: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 09: North America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

Table 10: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 11: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 12: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 13: Europe Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

Table 14: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 15: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 16: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 17: Asia Pacific Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

Table 18: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 19: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 20: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 21: Latin America Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027

Table 22: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

Table 23: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 24: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2027

Table 25: Middle East & Africa Nephropathic Cystinosis Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027